• Treatment Response at Week 48 [ Time Frame: At week 48 ]
• Time to Treatment Failure Through 48 Weeks of Treatment [ Time Frame: Week 48 ]

• Treatment Response at Week 24 [ Time Frame: Week 24 ]
• Treatment Response at Week 2 [ Time Frame: week 2 ]
• Treatment Response at Week 4 [ Time Frame: week 4 ]
• Treatment Response at Week 8 [ Time Frame: week 8 ]
• Treatment Response at Week 16 [ Time Frame: week 16 ]
• Treatment Response at Week 32 [ Time Frame: Week 32 ]
• Treatment Response at Week 40 [ Time Frame: Week 40 ]
• Treatment Response at Week 48 [ Time Frame: Week 48 ]
• Treatment Response at Week 56 [ Time Frame: week 56 ]
• Treatment Response at Week 64 [ Time Frame: week 64 ]
• Treatment Response at Week 72 [ Time Frame: Week 72 ]
• Treatment Response at Week 80 [ Time Frame: Week 80 ]
• Treatment Response at Week 88 [ Time Frame: Week 88 ]
• Treatment Response at Week 96 [ Time Frame: Week 96 ]
• Time to Treatment Failure Through 96 Weeks of Treatment [ Time Frame: Week 96 ]
• Time to Confirmed Virologic Failure Through 48 Weeks of Treatment [ Time Frame: Week 48 ]
• Time to Confirmed Virologic Failure Through 96 Weeks of Treatment [ Time Frame: Week 96 ]
• Virologic Response [ Time Frame: Week 2 through Week 96 (at any point during trial) ]
• Virologic Response at Week 2 [ Time Frame: Week 2 ]
• Virologic Response at Week 4 [ Time Frame: Week 4 ]
• Virologic Response at Week 8 [ Time Frame: Week 8 ]
• Virologic Response at Week 16 [ Time Frame: Week 16 ]
• Virologic Response at Week 24 [ Time Frame: Week 24 ]
• Virologic Response at Week 32 [ Time Frame: Week 32 ]
• Virologic Response at Week 40 [ Time Frame: Week 40 ]
• Virologic Response at Week 48 [ Time Frame: Week 48 ]
• Virologic Response at Week 56 [ Time Frame: Week 56 ]
• Virologic Response at Week 64 [ Time Frame: Week 64 ]
• Median Change From Baseline in Viral Load to Week 2 [ Time Frame: Baseline to Week 2 ]
• Median Change From Baseline in Viral Load to Week 4 [ Time Frame: Baseline to Week 4 ]
• Median Change From Baseline in Viral Load to Week 8 [ Time Frame: Baseline to Week 8 ]
• Median Change From Baseline in Viral Load to Week 16 [ Time Frame: Baseline to Week 16 ]
• Median Change From Baseline in Viral Load to Week 24 [ Time Frame: Baseline to Week 24 ]
• Median Change From Baseline in Viral Load to Week 32 [ Time Frame: Baseline to Week 32 ]
• Median Change From Baseline in Viral Load to Week 40 [ Time Frame: Baseline to Week 40 ]
• Median Change From Baseline in Viral Load to Week 48 [ Time Frame: Baseline to Week 48 ]
• Median Change From Baseline in Viral Load to Week 56 [ Time Frame: Baseline to Week 56 ]
• Median Change From Baseline in Viral Load to Week 64 [ Time Frame: Baseline to Week 64 ]
• Median Change From Baseline in Viral Load to Week 72 [ Time Frame: Baseline to Week 72 ]
• Median Change From Baseline in Viral Load to Week 80 [ Time Frame: Baseline to Week 80 ]
• Median Change From Baseline in Viral Load to Week 88 [ Time Frame: Baseline to Week 88 ]
• Median Change From Baseline in Viral Load to Week 96 [ Time Frame: Baseline to Week 96 ]
• Mean Change From Baseline to Week 2 in CD4+ Cell Count [ Time Frame: Baseline to Week 2 ]
• Mean Change From Baseline to Week 4 in CD4+ Cell Count [ Time Frame: Baseline to Week 4 ]
• Mean Change From Baseline to Week 16 in CD4+ Cell Count [ Time Frame: Baseline to Week 16 ]
• Mean Change From Baseline to Week 24 in CD4+ Cell Count [ Time Frame: Baseline to Week 24 ]
• Mean Change From Baseline to Week 32 in CD4+ Cell Count [ Time Frame: Baseline to Week 32 ]
• Mean Change From Baseline to Week 40 in CD4+ Cell Count [ Time Frame: Baseline to Week 40 ]
• Mean Change From Baseline to Week 48 in CD4+ Cell Count [ Time Frame: Baseline to Week 48 ]
• Mean Change From Baseline to Week 56 in CD4+ Cell Count [ Time Frame: Baseline to Week 56 ]
• Mean Change From Baseline to Week 64 in CD4+ Cell Count [ Time Frame: Baseline to Week 64 ]
• Mean Change From Baseline to Week 72 in CD4+ Cell Count [ Time Frame: Baseline to Week 72 ]
• Mean Change From Baseline to Week 80 in CD4+ Cell Count [ Time Frame: Baseline to Week 80 ]
• Mean Change From Baseline to Week 88 in CD4+ Cell Count [ Time Frame: Baseline to Week 88 ]
• Mean Change From Baseline to Week 96 in CD4+ Cell Count [ Time Frame: Baseline to Week 96 ]
• Time to New CDC Class C Progression Event or Death. [ Time Frame: after 48 weeks of treatment ]
• Virologic Response at Week 72 [ Time Frame: Week 72 ]
• Virologic Response at Week 80 [ Time Frame: Week 80 ]
• Virologic Response at Week 88 [ Time Frame: week 88 ]
• Virologic Response at Week 96 [ Time Frame: week 96 ]

Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.

• Drug: Tipranavir
• Drug: Ritonavir(r)
• Drug: Comparitor Protease Inhibitor (CPI)

Inclusion Criteria:

Patients meeting the following criteria will be eligible for participation in th is study:

1. Human Immunodeficiency virus 1 (HIV-1) infected males or females >=18 years of age.
2. Screening genotypic resistance report indicating both of the following: at least one primary protease Inhibitor (PI) mutation at the following sites:

30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M, and no more than two protease mutations on codons 33, 82, 84, or 90.

3. At least 3 consecutive months experience taking antiretrovirals (ARVs) from each of the classes of nucleoside reverse transcriptase inhibitors(NRTI(s)), non-nucleoside reverse transcriptase inhibitors(NNRTI(s)), and protease inhibitors (PIs) at some point in treatment history,with at least 2 protease inhibitor (PI)-based regimens, one of which must be the current regimen, and current protease inhibitor (PI)-based antiretroviral (ARV) medication regimen for at least 3 months prior to randomization.

4. Human Immunodeficiency Virus 1 (HIV-1) viral load >=1,000 copies/mL at screening.

Exclusion criteria:

Patients with any of the following criteria are excluded from participation in t he study:

1. Antiretroviral (ARV) medication naïve.
2. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the last 3 months.
3. alanine aminotransferase (ALT) >=3.0x upperlimit of normal (ULN) and aspartate aminotransferase(AST) >=2.5x upper limit of normal (ULN) (>=Division of AIDS(DAIDS) Grade 1) at either screening visit.